Jadenu Sprinkle (Deferasirox) Patent Expiration, LOE Window & CMS Spending

Jadenu Sprinkle (Deferasirox) by Novartis: Off-Patent Genericized (AB Competition), 6 AB generics, $1.4M 2024 CMS Part D & Medicaid spend, and 9 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN207968 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors6
2024 CMS Total Public Spend$1.4M
2024 Medicare Part D Spend$87K
2024 Medicaid Spend$1.3M
Reported Wholesale Price Change (CA SB 17)9 WAC filings (max 24.4% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.